Modality
ASO
MOA
BCL-2i
Target
PD-1
Pathway
Fibrosis
HCC
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
~May 2018
→ ~Aug 2019
Phase 2
Nov 2019
→ Apr 2029
Phase 2Current
NCT04315413
1,625 pts·HCC
2019-11→TBD·Terminated
NCT05274238
2,369 pts·HCC
2024-06→2029-04·Active
3,994 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-04-263.1y awayPh2 Data· HCC
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2
Termina…
P2
Active
Catalysts
Ph2 Data
2029-04-26 · 3.1y away
HCC
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04315413 | Phase 2 | HCC | Terminated | 1625 | HAM-D |
| NCT05274238 | Phase 2 | HCC | Active | 2369 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 |